Blacklisted Bliss GVS blames delayed re-registration for 'fake' drug issue in Ghana
This article was originally published in Scrip
India's Bliss GVS Pharma, which has been blacklisted in Ghana following allegations of supplying a fake antimalarial there, has denied any quality concerns and blamed a delay in re-registration of its products for the regulatory agency's action.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.